ASPIrin in Reducing Events in Dialysis ( ASPIRED )
ASPIrin in Reducing Events in Dialysis
Guangdong Provincial People's Hospital
9,000 participants
Jul 30, 2020
INTERVENTIONAL
Conditions
Summary
People with kidney failure requiring dialysis have a much higher risk of developing cardiovascular (CV) disease compared with the general population. A cardiac cause accounts for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time, this population has increased risks of clotting as well as bleeding episodes. While aspirin is known to reduce cardiovascular complications in the general population, evidence to support the use of aspirin in people with ESKD receiving dialysis therapy is currently lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin use in dialysis patients safely improves outcomes compared with no aspirin use.
Eligibility
Inclusion Criteria3
- Incident or prevalent adults (≥18 years old) dialysis patients are included in the Dialysis Registry.
- Commenced on dialysis with the expectation of ongoing maintenance dialysis requirement.
- Willing and able to provide informed consent for this study.
Exclusion Criteria6
- Requirement for any form of antiplatelet agent (aspirin, glycoprotein IIb/IIIa inhibitors etc), or oral anticoagulation (warfarin, NOACs), in the view of the treating physician.
- Contraindication to aspirin, in the view of the treating physician.
- Dialysis requirement due to acute kidney injure with expectation of kidney function recovery.
- History of haemorrhagic stroke or intracranial bleed within 12 months of screening.
- Coagulopathy from any cause.
- Unable to provide informed consent.
Interventions
Aspirin 100 mg tablet daily
Matching Placebo 1 pill daily
Locations(139)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04381143